References
- World Health Organization. Safety of Medicines. A guide to detecting and reporting adverse drug reactions. Geneva, Switzerland: World Health Organization; 2002. HO/EDM/QSM/2002.2.
- Pirmohamed M, James S, Meakin S. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329:15–19.
- Patel H, Bell D, Molokhia M, et al. Trends in hospital admissions for adverse drug reactions in England: analysis of national hospital episode statistics 1998–2005. BMC Clin Pharmacol. 2007;7:9.
- Lazarou J, Pomeranz BH, Corey PN. The incidence of adverse drug reactions in hospitalized patients-a meta- analysis of prospective studies. JAMA. 1998;279:1200–1205.
- Wester K, Jönsson AK, Spigset O, et al. Incidence of fatal adverse drug reactions: a population based study. Brit J Clin Pharmacol. 2008; 65(4):573–579.
- Alhawassi TM, Krass I, Bajorek BV, et al. A systematic review of the prevalence and risk factors for adverse drug reactions in the elderly in the acute care setting. Clin Interv Aging. 2014;9:2079–2086.
- Oscanoa TJ, Lizaraso F, Carvajal A. Hospital admissions due to adverse drug reactions in the elderly. A meta-analysis. Eur J Clin Pharmacol. 2017 Jun;73(6):759–770.
- Shepherd G, Mohorn P, Yacoub K, et al. Adverse drug reaction deaths reported in United States vital statistics, 1999-2006. Ann Pharmacother. 2012;46(2):169–175.
- Bouvy JC, De Bruin ML, Koopmanschap MA. Epidemiology of adverse drug reactions in Europe: a review of recent observational studies. Drug Saf. 2015;38(5):437–453.
- Aljadhey H, Mahmoud MA, Mayet A, et al. Incidence of adverse drug events in an academic hospital: a prospective cohort study. Int J Qual Health Care. 2013 Dec;25(6):648–655.
- Pirmohamed M, Breckenbridge AM. Adverse drug reactions. BMJ. 1998;316.
- World Health Organization. The WHO programme for international drug monitoring. [ cited 2017 Sep 5]. Available from: http://www.who.int/medicines/areas/quality_safety/safety_efficacy/National_PV_Centres_Map/en/
- Alharf A, Alqahtani N, Saeed G, et al. Saudi Vigilance Program: challenges and lessons learned. Saudi Pharm J. 2018;26(3):388–395.
- Alshammari TM, Alshakka M, Aljadhey H. Pharmacovigilance system in Saudi Arabia. Saudi Pharm J. 2017;25(3):299–305.
- Aljadhey H, Mahmoud MA, Alshammari TM, et al. A qualitative exploration of the major challenges facing pharmacovigilance in Saudi Arabia. Saudi Med J. 2015;36(9):1097–1102.
- Alshammari TM, Al-Kathiri WH, Louet HL, et al. Completeness of adverse drug reactions reports of the Saudi adverse event reporting system. Saudi Med J. 2015;36(7):821–828.
- Bawazir SA. Attitude of community pharmacists in Saudi Arabia towards adverse drug reaction reporting. Saudi Pharm J. 2006;14(1):75–83.
- Khan TM. Community pharmacists’ knowledge and perceptions about adverse drug reactions and barriers towards their reporting in Eastern region, Alahsa, Saudi Arabia. Ther Adv Drug Saf. 2013;4(2):45–51.
- Pourhoseingholi MA, Vahedi M, Rahimzadeh M. Sample size calculation in medical studies. Gastroenterol Hepatol Bed Bench. 2013;6(1):14.
- Adam M, Alswaida Y, Alshammari T. Community pharmacists’ knowledge, behaviors and experiences about adverse drug reaction reporting in Saudi Arabia. Saudi Pharm J. 2014;22(5):411–418.
- Hadi MA, Helwani R, Long CM. Facilitators and barriers towards adverse drug reaction reporting: perspective of Malaysian hospital pharmacists. J Pharm Health Serv Res. 2013;4:155–158.
- Liu J, Zhou Z, Yang S, et al. Factors that affect adverse drug reaction reporting among hospital pharmacists in Western China. Int J Clin Pharm. 2015;37(3):457–464.
- World Health Organization. Legal status of traditional medicine and complementary/alternative medicine: a worldwide review. Geneva, Switzerland: World Health Organization; 2001. WHO/EDM/TRM/2001.2.
- Al-Arifi MN. Availability and needs of herbal medicinal information resources at community pharmacy, Riyadh region, Saudi Arabia. Saudi Pharm J. 2013;21(4):351–360.